Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    423 result(s) found for: Retinal diseases. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000800-13 Sponsor Protocol Number: V1 Start Date*: 2013-01-24
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Influence of sustained-release dexamethasone on intraocular cytokines and growth factors and retinal blood vessels in retinal vein occlusion
    Medical condition: Retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10066426 Hemiretinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002790-11 Sponsor Protocol Number: V4.0 Start Date*: 2015-06-08
    Sponsor Name:Ludwig-Maximilians Universität München
    Full Title: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004656-38 Sponsor Protocol Number: CRF002EVA Start Date*: 2015-03-11
    Sponsor Name:Prof. Dr. Karl-Heinz Emmerich
    Full Title: Assessment of the suitability of serum VEGF level as diagnostic factor in macula edema caused by retinal or central retinal vein occlusion under therapy with Lucentis® (ranibizumab)
    Medical condition: Central retinal vein occlusion Retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001678-25 Sponsor Protocol Number: 138/06 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for vascular retinopathy a interventional study.
    Medical condition: vascular retinopathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038923 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020441-27 Sponsor Protocol Number: CORaLa Start Date*: 2011-02-23
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of ...
    Medical condition: macular edema secondary to non-ischemic central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10054467 Macular edema LLT
    14.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005473-20 Sponsor Protocol Number: V121102015 Start Date*: 2016-11-23
    Sponsor Name:UZ Leuven
    Full Title: Pilot study on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion.
    Medical condition: Patients with central retinal vein occlusion (CRVO)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000742-35 Sponsor Protocol Number: RTBAIEOP018 Start Date*: 2021-05-05
    Sponsor Name:ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: PROTOCOL FOR THE DIAGNOSIS AND THERAPY OF INTRAOCULAR RETINOBLASTOMA
    Medical condition: Intraocular retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000681-42 Sponsor Protocol Number: CoRaLa_II Start Date*: 2020-08-24
    Sponsor Name:Justus-Liebig University Gießen
    Full Title: Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion
    Medical condition: Macular edema due to central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005439-10 Sponsor Protocol Number: RabOCT Start Date*: 2013-08-30
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retin...
    Medical condition: macular edema secondary to branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10054467 Macular edema LLT
    18.1 100000004853 10038906 Retinal vein branch occlusion LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010973-19 Sponsor Protocol Number: 14130 Start Date*: 2009-09-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondar...
    Medical condition: Maculare edema secondary to Central Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) LV (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000440-63 Sponsor Protocol Number: GR41984 Start Date*: 2020-09-30
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL ...
    Medical condition: Macular edema secondary to Branch Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PT (Completed) AT (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000165-20 Sponsor Protocol Number: OZUROFT01/12 Start Date*: 2012-04-13
    Sponsor Name:Fundación para la Investigación biomédica del Hospital Universitario Ramón y Cajal. Madrid
    Full Title: SEQUENTIAL CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB AS RESCUE TREATMENT OF RECURRENT MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH OZURDEX
    Medical condition: Macular edema secondary to retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023900-29 Sponsor Protocol Number: MAF-AGN-OPH-RET-004 Start Date*: 2011-08-23
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion
    Medical condition: Macula oedema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002193-37 Sponsor Protocol Number: CHAD1031 Start Date*: 2014-09-05
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: A phase 3 multi-centre double-masked randomised controlled trial of adjunctive intraocular and periocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretina...
    Medical condition: retinal detachment and the development of scarring (proliferative vitreoretinopathy) in patients with open globe trauma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10057896 Proliferative vitreoretinopathy LLT
    17.0 10015919 - Eye disorders 10038848 Retinal detachment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-023110-30 Sponsor Protocol Number: Octome Start Date*: 2011-04-11
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases
    Medical condition: Macular oedema related to retinal vascular diseases
    Disease: Version SOC Term Classification Code Term Level
    10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010336-18 Sponsor Protocol Number: HCU01-09 Start Date*: 2010-02-15
    Sponsor Name:Maria Antonia Saornil Alvarez
    Full Title: Influencia del acetónido de triamcinolona y del ranibizumab en la retinopatía post irradiación en el melanoma de úvea
    Medical condition: Retinopatía post-radiación en el melanoma de úvea
    Disease: Version SOC Term Classification Code Term Level
    9 10038923 Retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004731-12 Sponsor Protocol Number: uni-koeln-1782 Start Date*: 2016-07-20
    Sponsor Name:University of Cologne
    Full Title: Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment
    Medical condition: Primary rhegmatogenous retinal detachment (RRD) accompanied by elevated protein levels in anterior chamber fluid (laser flare value ≥15pc/ms).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000441-13 Sponsor Protocol Number: GR41986 Start Date*: 2020-08-27
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL ...
    Medical condition: Macular edema secondary to Central Retinal or Hemiretinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) AT (Completed) CZ (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004010-26 Sponsor Protocol Number: THR-317-003 Start Date*: 2018-08-03
    Sponsor Name:ThromboGenics NV
    Full Title: A Phase 2, open-label, multi-centre study to assess the efficacy and safety of intravitreal THR-317 for the treatment of macular telangiectasia Type 1 (MacTel 1)
    Medical condition: Macular Telangiectasia Type 1 (MacTel 1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038899 Retinal telangiectasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001085-10 Sponsor Protocol Number: CRFB002AGB17 Start Date*: 2014-09-08
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 17:48:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA